Progress with thiazolidinediones in the management of type 2 diabetes mellitus

Clinical Therapeutics

Volumn 26, Issue 2, 2004, Pages 177-190

  Meriden, Terry ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Ctrl IL Diabet and Metab Inst   (United States)

Author keywords

Cardiovascular events; Insulin resistance; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; C REACTIVE PROTEIN; FAT; FATTY ACID; GLIBENCLAMIDE; GLIMEPIRIDE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PROINSULIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING DISORDER; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; EDEMA; FIBRINOLYSIS; FLUID RETENTION; HUMAN; INFLAMMATION; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER INJURY; LIVER TOXICITY; MEDLINE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PREVALENCE; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULARIZATION; WEIGHT GAIN;

EID: 1542511335     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90017-3     Document Type: Article

References (96)

1. Collins FM. Current treatment approaches to type 2 diabetes mellitus: Successes and shortcomings. Am J Manag Care. 2002;8(Suppl 16):S460-S471.
2. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
3. American Diabetes Association. Consensus Development Conference on Insulin Resistance: 5-6 November 1997. Diabetes Care. 1998;21:310-314.
4. American Association of Clinical Endocrinologists and the American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management -2002 update. Endocr Pract. 2002;8(Suppl 1):40-82.
5. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
6. Stratton IM, Adler AI, Neil HA, et al, for the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412.
7. Stern M. Natural history of macrovascular disease in type 2 diabetes: Role of insulin resistance. Diabetes Care. 1999;22(Suppl 3):C2-C5.
8. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones [published correction appears in Ann Intern Med. 2001;135:307]. Ann Intern Med. 2001;134:61-71.
9. Uwaifo GI, Ratner RE. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med. 2003;115(Suppl 8A):12S-19S.
10. Wyne KL, Drexler AJ, Miller JL, et al. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med. 2003;special number:63-72.
11. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 2001;414:821-827.
12. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
13. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: Findings from a national cohort of US adults. Am J Epidemiol. 1997;146:214-222.
14. Ford ES, Mokdad AH. Fruit and vegetable consumption and diabetes mellitus incidence among U.S. adults. Prev Med. 2001;32:33-39.
15. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
16. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: A balanced overview. Diabetes Care. 1992;15:318-368.
17. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA. 2002;287:360-372.
18. Balfour JA, Plosker GL. Rosiglitazone. Drugs. 1999;57:921-930.
19. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care. 2000;23:557. Letter.
20. Lebovitz HE, Dole JF, Patwardhan R, et al, for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes [published correction appears in J Clin Endocrinol Metab. 2001;86:1659]. J Clin Endocrinol Metab. 2001;86:280-288.
21. Osei K, Miller EE, Everitt DE, et al. Rosiglitazone is effective and well tolerated as monotherapy in African Americans with type 2 diabetes. Diabetes. 2001;50 (Suppl 1):A127-A128. Abstract.
22. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278-284.
23. Rosenblatt S, Miskin B, Glazer NB, et al, for the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12:413-423.
24. Schneider R, Lessem J, Lekich R. Pioglitazone is effective in the treatment of patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1):A109. Abstract.
25. Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulfonylurea. Diabetes. 2001;50(Suppl 1):A135. Abstract.
26. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial [published correction in JAMA. 2000;284:1384]. JAMA. 2000;283:1695-1702.
27. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23:1792-1823.
28. Egan J, Rubin C, Mathisen A. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1):A117. Abstract.
29. Egan J, Rubin C, Mathisen A. Adding pioglitazone to metformin therapy improves the lipid profile in patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1): A106. Abstract.
30. Lawrence JM, Reckless JP. Pioglitazone. Int J Clin Pract. 2000;54:614-618.
31. Rubin C, Egan J, Schneider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1):A110. Abstract.
32. Schneider R, Egan J, Houser V. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes. Diabetes. 1999;48(Suppl 1):A106. Abstract.
33. Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care. 2002;25:1251-1252. Letter.
34. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Diabetes. 2001;50 (Suppl 2):A106. Abstract.
35. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
36. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-1297.
37. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
38. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
39. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
40. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care. 2002;25:1177-1184.
41. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes. 2001;50(Suppl 2):A38. Abstract.
42. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98:398-404.
43. Olefsky JM, Saltiel AR. PPAR γ and the treatment of insulin resistance. Trends Endocrinol Metab. 2000;11:362-368.
44. Festa A, D'Agostino RJr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
45. Festa A, D'Agostino R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19:562-568.
46. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
47. Haverkate F, Thompson SG, Pyke SD, et al, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
48. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
49. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive potein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
50. Ebeling P, Teppo AM, Koistinen HA, Koivisto VA. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism. 2001;50:283-287.
51. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
52. Kato K, Satoh H, Endo Y, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun. 1999;258:431-435.
53. phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): Evidence of a potent anti-inflammatory effect. Diabetes. 2001;50(Suppl 2):A68. Abstract.
54. Suzuki M, Takamisawa I, Suzuki K, et al. Close association between insulin resistance and vascular endothelial dysfunction in subjects with type 2 diabetes and improvement by pioglitazone. Diabetes. 2002;51 (Suppl 2):A304. Abstract.
55. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med. 2003;115(Suppl 8A):62S-68S.
56. Freed M, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glyburide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(Suppl 1):A267. Abstract.
57. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 2000;49:147-150.
58. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17:7-12.
59. Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420-1426.
60. Sung BH, Izzo JL Jr, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999;34:83-88.
61. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:2058-2064.
62. Bakris GL, Dole JF, Porter LE, et al. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes. 2000;49(Suppl 1): A96. Abstract.
63. Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272:E989-E996.
64. Haffner SM, D'Agostino R Jr, Mykkänen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999;22:562-568.
65. Ovalle F, Bell DS. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract. 2002;8:406-410.
66. McGarry JD. Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51:7-18.
67. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
68. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
69. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23:1605-1611.
70. Freed MI, Ratner R, Marcovina SM, et al, for the Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
71. Ovalle F, Bell DSH. Differing effects of thiazolidinediones on LDL subfractions. Diabetes. 2001;50(Suppl 2):A453-A454. Abstract.
72. Cominacini L, Young MM, Capriati A, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 1997;40:1211-1218.
73. Noguchi N, Sakai H, Kato Y, et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis. 1996;123:227-234.
74. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. Am J Cardiol. 2000;86:5L-10L.
75. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Ther. 2002;24:378-396.
76. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708-711.
77. Mathisen AL, Schneider R, Rubin C, Houser V, for the Pioglitazone 026 Study Group. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetologia. 1999;42(Suppl 1): A227. Abstract.
78. Actos [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2002.
79. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2003.
80. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med. 2003;115(Suppl 8A):37S-41S.
81. Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res. 2002;10:1008-1015.
82. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797-802.
83. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784-2791.
84. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46:983-988.
85. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 1999;48:1600-1606.
86. Porter LE, Freed MI, Jones NP, Biswas N. Rosiglitazone reduces proinsulin/insulin ratio and improves β-cell function in type 2 diabetes. Diabetologia. 2000;43 (Suppl 1):A192. Abstract.
87. Kawasaki F, Matsuda M, Kohara K, Kaku K. Rescue of beta-cell exhaustion after the development of diabetes mellitus in db/db mice. Diabetologia. 2001;44(Suppl 1): A147. Abstract.
88. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedi-one-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
89. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003;25:1017-1038.
90. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
91. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737-1743.
92. Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002;62:1463-1480.
93. Dogterom P, Jonkman JHG, Vallance SE. Rosiglitazone: No effect on erythropoiesis or premature red cell destruction. Diabetes. 1999;48(Suppl 1):A98. Abstract.
94. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108:2941-2948.
95. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25:815-821.
96. Rubin CJ, Schneider RL. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials. Diabetes. 2000;49(Suppl 1):A123. Abstract.